Interleukin-34 and immune checkpoint inhibitors: unified weapons against cancer

HIGHLIGHTS

• who: Fadhl Alshaebi and colleagues from the University of Wisconsin-Madison, United States have published the article: Interleukin-34 and immune checkpoint inhibitors: Unified weapons against cancer, in the Journal: (JOURNAL)
• what: An IL-34KO CT26 tumor cell model was conducted to determine if tumor-derived IL-34 Frontiers in Oncology frontiersin.org 10.3389/fonc.2023.1099696 the resistance, progression, and overall survival of patients.
• how: The results showed that the number of tumorinfiltrating Nos2+ M1-biased macrophages increased whereas the number of Arg1+ M2-biased macrophages decreased . This result is consistent . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.